Current Research Studies

SC-N150, SUMMIT Study

SC-N150, SUMMIT Study

  • Condition(s): Lymphoblastic Lymphoma (LBL), Malignant Bone Tumors, Medulloblastoma, Neuroblastoma, Newly diagnosed, Non-Hodgkin Lymphoma (NHL), Non-rhabdomyosarcoma Soft Tissue Sarcomas, Osteosarcoma, Pheochromocytoma, Pilocytic Astrocytoma, Recurrent and/or Refractory, Rhabdoid Tumor of the Kidney, Rhabdomyosarcoma, Soft Tissue Sarcomas, Solid Tumor, Thyroid Cancer, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Adrenal Tumors, Adrenocortical Carcinoma, Anaplastic Large Cell Lymphoma (ALCL), Atypical Teratoid/Rhabdoid Tumor, Behavioral, Brain Tumor, Burkitt's Lymphoma, CNS Embryonal Tumors, CNS Germ Cell Tumors, CNS Sarcoma, Chronic Myelogenous Leukemia (CML), Clear Cell Sarcoma of the Kidney, Craniopharyngioma, Diffuse Large B-cell Lymphoma (DLBCL), Ependymoma, Ewing Sarcoma, Germ Cell Tumors, Glioneuronal and Neuronal Tumors, Hepatoblastoma, Hepatocellular Carcinoma, Hodgkin Lymphoma, Leukemia & Lymphoma, Liver Tumors, Low-Grade Glioma
  • Phase: N/A
  • Clinicaltrials.gov ID: NCT05706610

What is the goal of the study?

A pilot feasibility randomized clinical trial comparing a tailored intervention to uniform standard of care will be conducted. A total of 40 AYAs with cancer will be randomized to one of the two programs. Data will be collected to explore the hypotheses that the intervention meets pre-established enrollment, retention, fidelity, and data completion feasibility criteria and that AYAs will rate the intervention as easy to use and acceptable.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: